So I am definitely in favor of a buyout but if you are the BP machine and you need this ruling overturned I think you want it to be Amarin’s name in the headline. But, you buy a piece of the company to control the strategy and when you buyout the rest later your overall cost us less. Let Pfizer, Amgen, Gilead, Astra or any other buy 25% in the open market.
Would be more prudent to partner with different Pharma companies in each European country. Piggie back off existing salesforce. No overhead. Focus on growing US market. Develop Vascepa sales and then drop price when generics enter the market. Meanwhile, you can appeal decision.
Market Data 
Markets 
AI
